Published August 1, 2025 | Version v1
Journal article Open

STAPHYLOCOCCUS AUREUS VACCINE: OPPORTUNITIES AND CHALLENGES AHEAD OF ROLLOUT

Authors/Creators

  • 1. Department of Preventive and Social Medicine, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand (India).

Description

Staphylococcus aureus is a ubiquitous gram-positive pathogen responsible for a wide range of illnesses—from mild skin infections to life-threatening diseases such as endocarditis, pneumonia, bacteremia, and sepsis. Its increasing antibiotic resistance and immune evasion strategies make it a formidable public health threat, articularly in hospital and community settings. Despite decades of effort, there is no approved vaccine available against S. aureus. This article delves into the historical evolution of vaccine candidates, explores reasons for past failures, and reviews emerging approaches in vaccine design—highlighting the urgent need for multi-antigenic, immune-stimulating strategies that address pathogen variability and host response diversity.

Files

6 WJPSR 1420.pdf

Files (782.6 kB)

Name Size
md5:1bbca0eb503f9dcc24e7869a128ea117
782.6 kB Preview Download

Additional details

References

  • 1. Shinefield HR, Black S. Prevention of Staphylococcus aureus infections: advances in vaccine development. Expert Rev Vaccines, 2005; 4(5): 669–76.
  • 2. Chand U, Priyambada P, Kushawaha PK. Staphylococcus aureus vaccine strategy: Promise and challenges. Microbiol Re, 2023; 271: 127362.
  • 3. Scafa-Udriste A, Popa MI, Popa GL. Updates on staphylococcal vaccines. Microbiol Res, 2023; 15(1): 137–51.
  • 4. Ohlsen K, Lorenz U. Immunotherapeutic strategies to combat staphylococcal infections. Int J Med Microbiol, 2010; 300(6): 402–10.
  • 5. Shinefield H, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med, 2002; 346(7): 491–6.
  • 6. Wong Fok Lung T, et al. Staphylococcus aureus adaptive evolution: immune evasion and vaccine development. Front Cell Infect Microbiol, 2022; 12: 1060810.
  • 7. McNeely TB, et al. Mortality among recipients of the Merck V710 S. aureus vaccine. Hum Vaccin Immunother, 2014; 10(12): 3513–6.
  • 8. Schmidt CS, et al. NDV-3 vaccine for Candida and S. aureus is safe and immunogenic. Vaccine, 2012; 30(52): 7594–600.
  • 9. Bavari S, et al. Superantigen vaccines: SEB mutant studies. J Infect Dis, 1996; 174(2): 338–45.
  • 10. Scully IL, et al. Performance of a four-antigen S. aureus vaccine in preclinical models. Microorganisms, 2021; 9(1): 177.
  • 11. Giersing BK, et al. Status of vaccine R&D for S. aureus. Vaccine, 2016; 34(26): 2962–6.
  • 12. Jansen KU, et al. S. aureus vaccines: Problems and prospects. Vaccine, 2013; 31(25): 2723–30.
  • 13. Mancini F, et al. 4C-Staph vaccine elicits protective responses in mice. PLoS One, 2016; 11(1): e0147767.